{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-033946","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.305280+00:00","generated_at":"2026-05-23T09:36:11.439425+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CERo raises up to $8M in Series D convertible; believes meets Nasdaq equity requirement","bullets":["Closed initial $5M of up to $8M Series D convertible preferred; conversion price $0.78, floor $0.156.","Believes meets $2.5M stockholders' equity after placement, prior $2.3M equity line & $4.1M Feb offering; delisting risk remains.","Series D ranks senior to Series A & B, pari passu with Series C; 25% redemption premium on bankruptcy or company optional redemption.","Proceeds to fund IND allowances, MDACC site activation, and extend cash runway, per press release."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-033946","json":"https://secwatch.observer/filing/0001213900-25-033946.json","markdown":"https://secwatch.observer/filing/0001213900-25-033946.md","text":"https://secwatch.observer/filing/0001213900-25-033946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025033946/0001213900-25-033946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025033946/ea0238925-8k_cerotherap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T09:36:11.439425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}